FDA restricts Keytruda, Tecentriq monotherapy

FDA restricted the labels of Keytruda pembrolizumab and Tecentriq atezolizumab as monotherapy for urothelial cancer in a first-line setting.

The update applies to Keytruda or Tecentriq's use in locally advanced or metastatic urothelial carcinoma to patients ineligible for cisplatin-containing therapy who have PD-L1-expressing tumors, and to patients ineligible for platinum-containing chemotherapy regardless of PD-L1 status...